MedTrace Logo

Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication

NCT04907747 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2021-06-01

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of vonoprazan compared with esomeprazole as first-line treatment for Helicobacter Pylori(Hp) eradication, as well as the safety and economic benefits.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Vonoprazan

Potassium-competitive acid blocker

DRUG

Esomeprazole

Proton pump inhibitor

DRUG

Colloidal bismuth pectin

Gastric mucosal protective drug with anti-H. pylori effect

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

DRUG

Furazolidone

Antibiotic for H. pylori eradication

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-18
Primary Completion
2022-04-13
Completion
2022-04-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04907747 on ClinicalTrials.gov